Randomised phase II trial of irinotecan plus cisplatin vs irinotecan, cisplatin plus etoposide repeated every 3 weeks in patients with extensive-disease small-cell lung cancer.

Br J Cancer · 2008 · PMC2259188 · PMID 18253118

Europe PMC DOI

hedged sentence

0.0540

closest p · 1.1× alpha

0.0540

boldest claim

The sentences

marginal significanceP =0.054so close (0.05 < p ≤ 0.1)

Grade 3–4 fatigue was more common in the IPE arm with marginal significance (2 vs 11%, P =0.054).

also in 2,822 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.